Hypomimia in triggered smiling in patients with Parkinson’s disease
Objective: We aimed to evaluate if Parkinson’s disease (PD) patients show decreased micro expressions in spontaneous laughing according to Action Units (AU) activation. Background: Hypomimia,…Barriers to Healthcare Utilization and Adherence to Medications among People Living with Parkinson’s Disease in Senegal
Objective: To explore the barriers to healthcare utilization and adherence to medications among people living with Parkinson’s disease in Senegal, and propose context-informed strategies to…Studying the relationship between interoceptive awareness, caregiver burden, and disease perception in Parkinson’s Disease
Objective: Analyze the impact of interoceptive awareness deficits on caregiver burden in Parkinson's disease. Background: Interoceptive awareness (IA) is the ability to perceive and process…Aquatic Interval Training in Individuals with Parkinson’s Disease: Can It Improve Gait?
Objective: To identify changes in gait speed and gait-related activities after an aquatic interval training physiotherapy program in individuals with PD. Background: Parkinson's disease (PD)…Cerebrospinal fluid DOPA decarboxylase levels as a marker of disease severity in Parkinson’s Disease
Objective: To assess the correlation of CSF DDC levels to DaT-SPECT SBR in PD and iRBD. Background: Raised cerebrospinal fluid (CSF) proteomic biomarker, DOPA decarboxylase…Long term real-world monitoring supports the superiority of adaptive deep brain stimulation: preliminary data on three patients with Parkinson’s disease
Objective: Describe the preliminary results of adaptive deep brain stimulation (aDBS) treatment for Parkinson’s disease (PD) and the value of real-world monitoring in defining clinical…Comparative efficacy of opicapone and entacapone in the management of motor fluctuations in Parkinson’s disease
Objective: To compare the clinical efficacy of two catechol-O-methyltransferase (COMT) inhibitors, opicapone (OPC) and entacapone (ENT). Background: OPC and ENT are used as adjunctive therapy…Methodological considerations supporting a time-to-event primary endpoint in the PADOVA study in early-stage Parkinson’s disease participants on stable symptomatic treatment
Objective: To provide the methodological rationale for using a time-to-event (TTE) primary endpoint in the PADOVA study. Background: The use of symptomatic medications represents a…Continuous subcutaneous foslevodopa/foscarbidopa infusion therapy leads to a sustained reduction in dyskinesias in Parkinson’s disease
Objective: To assess the longitudinal effect of continuous subcutaneous foslevodopa/foscarbidopa infusion therapy on dyskinesias as measured by the Unified Dyskinesia Rating Scale (UDysRS) total score…Targeting inflammation and autophagy: a dual-inhibition strategy to reduce α-synuclein pathology in GBA1-associated Parkinson’s disease
Objective: To assess the effects of combined inhibition of mTOR (autophagy regulator) and STING (inflammation regulator) on α-synuclein phosphorylation, tyrosine hydroxylase expression, and lysosphingolipid levels in…
- « Previous Page
- 1
- …
- 70
- 71
- 72
- 73
- 74
- …
- 436
- Next Page »